Curative Biotechnology Inc | Business Contracts

Seventh Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on January 25, 2023)

Seventh Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on January 13, 2023)

Sixth Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on January 9, 2023)

Second Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)

Third Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)

Fourth Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)

Fifth Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 30, 2022)

Form of Underwriting Agreement (Filed With SEC on November 7, 2022)

Specimen of Common Stock Certificate (Filed With SEC on November 7, 2022)

Specimen Series A Preferred Stock (Filed With SEC on November 7, 2022)

Specimen of Series B Preferred Stock (Filed With SEC on November 7, 2022)

Specimen of Series C Preferred Stock (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase Warrant issued to Certain Consultants in May 2021 (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase Warrant issued to Investors in August 2021 (Filed With SEC on November 7, 2022)

Form of Warrant issued to investors on May 21, 2021 (Filed With SEC on November 7, 2022)

Form of Warrant issued to Investors in Note Offering from November 2020 through January 2021 (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase warrant issued to Consultant on December 3, 2020 (Filed With SEC on November 7, 2022)

Form of Consultant Warrants issued between December 2020 and January 2021 (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase Warrant issued to Paul Michaels on June 11, 2021 (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase Warrant issued to Marc Drimer on July 14, 2021 (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase Option issued to Catherine Sohn pursuant to Consulting Agreement dated September 27, 2021 (Filed With SEC on November 7, 2022)

2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)

Form of Stock Option Grant for 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)

Form of Restricted Stock Award Agreement for 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)

Form of Restricted Stock Unit Agreement for 2021 Equity Incentive Plan (Filed With SEC on November 7, 2022)

Form of Underwriter Warrant (Filed With SEC on November 7, 2022)

Form of warrant to be issued in Underwritten Offering (Filed With SEC on November 7, 2022)

Form of Subscription Agreement for Investor Offerings in August 2021 (Filed With SEC on November 7, 2022)

Form of Subscription Agreement for Investor Offerings on May 21, 2021 (Filed With SEC on November 7, 2022)

Form of Note Issued to Investors between November 2020 and January 2021 (Filed With SEC on November 7, 2022)

Settlement Agreement dated August 9, 2021 (Filed With SEC on November 7, 2022)

Consulting Agreement dated September 27, 2021 (Filed With SEC on November 7, 2022)

Employment Agreement with Richard Garr dated October 1, 2020 (Filed With SEC on November 7, 2022)

Employment Agreement with Barry Ginsberg dated October 1, 2020 (Filed With SEC on November 7, 2022)

Employment Agreement with Paul Michaels dated October 1, 2020 (Filed With SEC on November 7, 2022)

License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on November 7, 2022)

Exclusive Option Agreement for Purchase of Patent Rights dated September 30, 2020 between Curative Biotechnology (fka Connectyx Technologies Holdings Group) and IEM Inc (Filed With SEC on November 7, 2022)

Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group) (Filed With SEC on November 7, 2022)

Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on November 7, 2022)

License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on November 7, 2022)

First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on November 7, 2022)

First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on November 7, 2022)

Securities Purchase Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)

Secured Convertible Promissory Note for March 2022 Offering (Filed With SEC on November 7, 2022)

Security Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)

Intellectual Property Security Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)

Warrant for March 2022 Offering (Filed With SEC on November 7, 2022)

Form of Lock Up Agreement for March 2022 Offering (Filed With SEC on November 7, 2022)

Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Filed With SEC on November 7, 2022)

Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on November 7, 2022)

Form of Warrant Agency Agreement (Filed With SEC on November 7, 2022)

Form of Common Stock Purchase Option issued to Catherine Sohn pursuant to Consulting Agreement dated September 27, 2021 (Filed With SEC on September 30, 2022)

Form of Underwriter Agreement (Filed With SEC on September 28, 2022)

Settlement Agreement dated August 9, 2021 (Filed With SEC on September 9, 2022)

Consulting Agreement dated September 27, 2021 (Filed With SEC on September 9, 2022)

License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on September 9, 2022)

Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on September 9, 2022)

License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on September 9, 2022)

First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on September 9, 2022)

First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on September 9, 2022)

Securities Purchase Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)

Secured Convertible Promissory Note for March 2022 Offering (Filed With SEC on September 9, 2022)

Security Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)

Intellectual Property Security Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)

Warrant for March 2022 Offering (Filed With SEC on September 9, 2022)

Form of Lock Up Agreement for March 2022 Offering (Filed With SEC on September 9, 2022)

Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on September 9, 2022)

Amendment to March 2022 Convertible Note Transaction Documents (Filed With SEC on September 1, 2022)

Underwriter Agreement (Filed With SEC on August 1, 2022)

Form of Common Stock Purchase Warrant issued in Aegis Capital Underwritten Offering (Filed With SEC on August 1, 2022)

Form of Warrant Agent Agreement between Curative Biotechnology and Issuer Direct Corporation (Filed With SEC on August 1, 2022)

Form of Underwriter Warrant (Filed With SEC on August 1, 2022)

Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Filed With SEC on April 25, 2022)

Specimen of Common Stock Certificate (Filed With SEC on April 15, 2022)

Specimen Series A Preferred Stock (Filed With SEC on April 15, 2022)

Specimen of Series B Preferred Stock (Filed With SEC on April 15, 2022)

Specimen of Series C Preferred Stock (Filed With SEC on April 15, 2022)

Form of Common Stock Purchase Warrant issued to Certain Consultants in May 2021 (Filed With SEC on April 15, 2022)

Form of Common Stock Purchase Warrant issued to Investors in August 2021 (Filed With SEC on April 15, 2022)

Form of Warrant issued to investors on May 21, 2021 (Filed With SEC on April 15, 2022)

Form of Warrant issued to Investors in Note Offering from November 2020 through January 2021 (Filed With SEC on April 15, 2022)

Form of Common Stock Purchase warrant issued to Consultant on December 3, 2020 (Filed With SEC on April 15, 2022)

Form of Consultant Warrants issued between December 2020 and January 2021 (Filed With SEC on April 15, 2022)

Form of Common Stock Purchase Warrant issued to Paul Michaels on June 11, 2021 (Filed With SEC on April 15, 2022)

Form of Common Stock Purchase Warrant issued to Marc Drimer on July 14, 2021 (Filed With SEC on April 15, 2022)

2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)

Form of Stock Option Grant for 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)

Form of Restricted Stock Award Agreement for 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)

Form of Restricted Stock Unit Agreement for 2021 Equity Incentive Plan (Filed With SEC on April 15, 2022)

Form of Subscription Agreement for Investor Offerings in August 2021 (Filed With SEC on April 15, 2022)

Form of Subscription Agreement for Investor Offerings on May 21, 2021 (Filed With SEC on April 15, 2022)

Form of Note Issued to Investors between November 2020 and January 2021 (Filed With SEC on April 15, 2022)

Settlement Agreement dated August 9, 2021 (Filed With SEC on April 15, 2022)

Consulting Agreement dated September 27, 2021 (Filed With SEC on April 15, 2022)

Employment Agreement with Richard Garr dated October 1, 2020 (Filed With SEC on April 15, 2022)

Employment Agreement with Barry Ginsberg dated October 1, 2020 (Filed With SEC on April 15, 2022)

Employment Agreement with Paul Michaels dated October 1, 2020 (Filed With SEC on April 15, 2022)

License, Funding and Operational Agreement dated October 1, 2021 between Curative Biotechnology, Inc., David Horn, LLC, and Mid-Atlantic BioTherapeutics, Inc (Filed With SEC on April 15, 2022)

Exclusive Option Agreement for Purchase of Patent Rights dated September 30, 2020 between Curative Biotechnology (fka Connectyx Technologies Holdings Group) and IEM Inc (Filed With SEC on April 15, 2022)

Patent License Agreement dated February 2, 2021 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx Technologies Holdings Group) (Filed With SEC on April 15, 2022)

Patent License Agreement -Exclusive Evaluation Option License dated October 15, 2020 between National Institute of Health and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on April 15, 2022)

License, Funding and Operational Agreement dated September 30, 2020 between Mid-Atlantic BioTherapeutics, Inc., David Horn, LLC, and Curative Biotechnology, Inc. (fka Connectyx... (Filed With SEC on April 15, 2022)

First Amendment to License, Funding and Operational Agreement dated December 30, 2021 between Mid-Atlantic BioTherapeutics and Curative Biotechnology, Inc (Filed With SEC on April 15, 2022)

First Amendment to License, Funding and Operational Agreement dated December 31, 2021 between Mid-Atlantic BioTherapeutics, Inc. and Curative Biotechnology, Inc (Filed With SEC on April 15, 2022)

Form of Securities Purchase Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)

Form of Secured Convertible Promissory Note for March 2022 Offering (Filed With SEC on April 15, 2022)

Form of Security Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)

Form of Intellectual Property Security Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)

Form of Warrant for March 2022 Offering (Filed With SEC on April 15, 2022)

Form of Lock Up Agreement for March 2022 Offering (Filed With SEC on April 15, 2022)

Cooperative Research and Development Agreement for Intramura-PhS Clinical Research (Filed With SEC on April 15, 2022)

Curative Biotechnology Inc (111)